Cargando…
Risk of severe illness of COVID‐19 patients with NAFLD and increased NAFLD fibrosis scores
BACKGROUND: There is still little knowledge about the association of liver fibrosis with the clinical outcomes of COVID‐19 patients with non‐alcoholic fatty liver disease (NAFLD). The aim of the study was to determine the association of NAFLD fibrosis score (NFS)–determined liver fibrosis with clini...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373321/ https://www.ncbi.nlm.nih.gov/pubmed/34213039 http://dx.doi.org/10.1002/jcla.23880 |
_version_ | 1783739923404161024 |
---|---|
author | Yao, Renling Zhu, Li Wang, Jian Liu, Jiacheng Xue, Ruifei Xue, Leyang Liu, Longgen Li, Chunyang Zhao, Haiyan Cheng, Juan Huang, Songping Li, Yang Zhao, Xiang‐an Zhu, Chuanwu Li, Ming Huang, Rui Wu, Chao |
author_facet | Yao, Renling Zhu, Li Wang, Jian Liu, Jiacheng Xue, Ruifei Xue, Leyang Liu, Longgen Li, Chunyang Zhao, Haiyan Cheng, Juan Huang, Songping Li, Yang Zhao, Xiang‐an Zhu, Chuanwu Li, Ming Huang, Rui Wu, Chao |
author_sort | Yao, Renling |
collection | PubMed |
description | BACKGROUND: There is still little knowledge about the association of liver fibrosis with the clinical outcomes of COVID‐19 patients with non‐alcoholic fatty liver disease (NAFLD). The aim of the study was to determine the association of NAFLD fibrosis score (NFS)–determined liver fibrosis with clinical outcomes of COVID‐19 patients with NAFLD. METHODS: The NAFLD was diagnosed by the Hepatic Steatosis Index (HSI) in the absence of other causes of chronic liver diseases. NFS was used to evaluate the severity of liver fibrosis. RESULTS: A total of 86 COVID‐19 patients with NAFLD were included. The median age was 43.5 years, and 58.1% of patients were male. Thirty‐eight (44.2%) patients had advanced liver fibrosis according to the NFS. Multivariate analysis indicated that concurrent diabetes (odds ratio [OR] 8.264, 95% confidence interval [CI] 1.202–56.830, p = 0.032) and advanced liver fibrosis (OR 11.057, 95% CI 1.193–102.439, p = 0.034) were independent risk factors of severe illness in COVID‐19 patients with NAFLD. CONCLUSION: NAFLD patients with NFS‐determined advanced liver fibrosis are at higher risk of severe COVID‐19. |
format | Online Article Text |
id | pubmed-8373321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83733212021-08-24 Risk of severe illness of COVID‐19 patients with NAFLD and increased NAFLD fibrosis scores Yao, Renling Zhu, Li Wang, Jian Liu, Jiacheng Xue, Ruifei Xue, Leyang Liu, Longgen Li, Chunyang Zhao, Haiyan Cheng, Juan Huang, Songping Li, Yang Zhao, Xiang‐an Zhu, Chuanwu Li, Ming Huang, Rui Wu, Chao J Clin Lab Anal Research Articles BACKGROUND: There is still little knowledge about the association of liver fibrosis with the clinical outcomes of COVID‐19 patients with non‐alcoholic fatty liver disease (NAFLD). The aim of the study was to determine the association of NAFLD fibrosis score (NFS)–determined liver fibrosis with clinical outcomes of COVID‐19 patients with NAFLD. METHODS: The NAFLD was diagnosed by the Hepatic Steatosis Index (HSI) in the absence of other causes of chronic liver diseases. NFS was used to evaluate the severity of liver fibrosis. RESULTS: A total of 86 COVID‐19 patients with NAFLD were included. The median age was 43.5 years, and 58.1% of patients were male. Thirty‐eight (44.2%) patients had advanced liver fibrosis according to the NFS. Multivariate analysis indicated that concurrent diabetes (odds ratio [OR] 8.264, 95% confidence interval [CI] 1.202–56.830, p = 0.032) and advanced liver fibrosis (OR 11.057, 95% CI 1.193–102.439, p = 0.034) were independent risk factors of severe illness in COVID‐19 patients with NAFLD. CONCLUSION: NAFLD patients with NFS‐determined advanced liver fibrosis are at higher risk of severe COVID‐19. John Wiley and Sons Inc. 2021-07-02 /pmc/articles/PMC8373321/ /pubmed/34213039 http://dx.doi.org/10.1002/jcla.23880 Text en © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Yao, Renling Zhu, Li Wang, Jian Liu, Jiacheng Xue, Ruifei Xue, Leyang Liu, Longgen Li, Chunyang Zhao, Haiyan Cheng, Juan Huang, Songping Li, Yang Zhao, Xiang‐an Zhu, Chuanwu Li, Ming Huang, Rui Wu, Chao Risk of severe illness of COVID‐19 patients with NAFLD and increased NAFLD fibrosis scores |
title | Risk of severe illness of COVID‐19 patients with NAFLD and increased NAFLD fibrosis scores |
title_full | Risk of severe illness of COVID‐19 patients with NAFLD and increased NAFLD fibrosis scores |
title_fullStr | Risk of severe illness of COVID‐19 patients with NAFLD and increased NAFLD fibrosis scores |
title_full_unstemmed | Risk of severe illness of COVID‐19 patients with NAFLD and increased NAFLD fibrosis scores |
title_short | Risk of severe illness of COVID‐19 patients with NAFLD and increased NAFLD fibrosis scores |
title_sort | risk of severe illness of covid‐19 patients with nafld and increased nafld fibrosis scores |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373321/ https://www.ncbi.nlm.nih.gov/pubmed/34213039 http://dx.doi.org/10.1002/jcla.23880 |
work_keys_str_mv | AT yaorenling riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT zhuli riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT wangjian riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT liujiacheng riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT xueruifei riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT xueleyang riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT liulonggen riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT lichunyang riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT zhaohaiyan riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT chengjuan riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT huangsongping riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT liyang riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT zhaoxiangan riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT zhuchuanwu riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT liming riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT huangrui riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores AT wuchao riskofsevereillnessofcovid19patientswithnafldandincreasednafldfibrosisscores |